Influence of safety warnings on ESA prescribing among dialysis patients using an interrupted time series

Mae Thamer1, Yi Zhang1, Dejian Lai2,3, Onkar Kshirsagar1 and Dennis Cotter1*

Abstract

Background: In March, 2007, a black box warning was issued by the Food and Drug Administration (FDA) to use the lowest possible erythropoiesis-stimulating agents (ESA) doses for treatment of anemia associated with renal disease. The goal is to determine if a change in ESA use was observed following the warning among US dialysis patients.

Methods: ESA therapy was examined from September 2004 through August 2009 (thirty months before and after the FDA black box warning) among adult Medicare hemodialysis patients. An interrupted time series model assessed the impact of the warnings.

Results: The FDA black box warning did not appear to influence ESA prescribing among the overall dialysis population. However, significant declines in ESA therapy after the FDA warnings were observed for selected populations. Patients with a hematocrit ≥36% had a declining month-to-month trend before (−164 units/week, p = <0.0001) and after the warnings (−80 units/week, p = .001), and a large drop in ESA level immediately after the black box (−4,744 units/week, p = <.0001). Not-for-profit facilities had a declining month-to-month trend before the warnings (−90 units/week, p = .009) and a large drop in ESA dose immediately afterwards (−2,487 units/week, p = 0.015). In contrast, for-profit facilities did not have a significant change in ESA prescribing.

Conclusions: ESA therapy had been both profitable for providers and controversial regarding benefits for nearly two decades. The extent to which a FDA black box warning highlighting important safety concerns influenced use of ESA therapy among nephrologists and dialysis providers was unknown. Our study found no evidence of changes in ESA prescribing for the overall dialysis population resulting from a FDA black box warning.

Keywords: Epoetin, ESA therapy, Black box warnings, Interrupted time series, Anemia management, ESRD

Background

Anemia affects nearly all end-stage renal disease (ESRD) patients and is associated with reduced quality of life and decreased survival rates [1-3]. In 1987, investigators reported successful use of erythropoietin stimulating agents (ESA also known as rHuEPO, epoetin or EPO, trade name EPOGEN*) in treating the anemia by elevating the hematocrit level of ESRD patients and reducing transfusions. Between 1991 and 2005, the mean ESA dose increased about four-fold in dialysis patients [4]. In 2007, Medicare expenditures for ESAs for ESRD patients were ~ $1.65 billion [5]. Randomized trials found an increase in vascular access thrombosis and a trend towards death and heart attacks among dialysis patients [6], and an increased risk of a composite endpoint including death and cardiovascular events among predialysis patients targeted to higher hematocrit levels [7]. A third study found no difference in harm or benefit in the study arms [8]. As a result, on March 9, 2007, FDA issued a black box public health warning to physicians to adjust the ESA dose to maintain the lowest hemoglobin level needed to avoid the need for blood transfusions. According to the FDA, “physicians and patients should carefully weigh the risks of ESAs against transfusion risks.” The goal of this study...
was to examine if providers changed their prescribing of ESA therapy as a result of the FDA warnings.

**Methods**

**Data sources and study design**

We used data from the United States Renal Data System (USRDS) Standard Analytic Files (SAFs) to conduct this study [9]. USRDS data system is a national resource that includes demographic and clinical data on ~97% of all US ESRD patients and their institutional providers of dialysis treatment. (The USRDS website, http://www.usrds.org, “Researcher’s Guide to the USRDS Database” describes the variables, data source, collection methods, and validation studies.) The hematocrit reading taken prior to the first administration of ESA therapy during the billing period (usually the beginning of the month) was submitted for payment with the total dose of ESA administered over the exposure period.

Specifically, *September 2004 to February 2007* was chosen as the 30-month base period (prior to the FDA black box warning) and *March 2007 to August 2009* was chosen as the 30-month follow-up period. ESA therapy is usually administered during outpatient dialysis via intravenous administration three times a week. In an effort to stabilize a large increase in hematocrit, physicians will periodically prescribe a zero ESA dose for a particular month. We also include these so-called zero dose months in our analysis.

To ensure the availability of claims, the study population was restricted to adult ESRD hemodialysis patients with Medicare as a primary payer indicated by a variable in the USRDS Payor History File. We excluded those patients with MSP because they have incomplete ESA data since their primary (usually private) payer is likely to get billed for ESA therapy. Our study period included only one form of ESA (alfa epoetin) for treatment of anemia associated with renal failure.

Covariates used for subanalyses are listed in Tables 1 & 2. Age was categorized as follows: 18 – 44, 45 – 64, and ≥65 years. Race was categorized as White or non-white. Duration of dialysis was determined as: <12, 12 – <36, and ≥36 months. Diabetes was determined if it was reported to be the primary cause of renal failure and/or diabetes was listed as a co-morbid condition when a patient enrolls in the Medicare ESRD program. Dialysis organizational status was defined by: 1) chain membership (based on size and affiliation); and 2) profit status.

**Interrupted time series analysis**

Trends in anemia treatment before and after the FDA Public Health Advisory were statistically analyzed by categorical methods and interrupted time series models [10,11]. To determine if there was a differential impact resulting from the FDA black box warning, we stratified our analyses by demographic, clinical, and facility characteristics.

---

**Table 1 Characteristics of patients receiving ESA therapy before and after the March 2007 FDA black box warning**

|                           | Entire study period | Base period | Follow up | P-value* |
|---------------------------|---------------------|-------------|-----------|----------|
| Number of patients months | 13,748,238          | 6,702,212   | 7,046,026 |          |
| Age (Year)                |                     |             |           |          |
| 18–44                     | 13.5                | 13.6        | 13.4      | <.0001   |
| 45–64                     | 37.9                | 37.1        | 38.6      |          |
| ≥65                       | 48.6                | 49.3        | 48.0      |          |
| Race                      |                     |             |           | 0.329    |
| White                     | 54.6                | 54.6        | 54.6      |          |
| Non-white                 | 45.4                | 45.4        | 45.4      |          |
| Gender                    |                     |             |           | <.0001   |
| Male                      | 53.7                | 53.4        | 53.9      |          |
| Female                    | 46.3                | 46.6        | 46.1      |          |
| Duration of dialysis      |                     |             |           | <.0001   |
| <12 months                | 20.3                | 21.2        | 19.5      |          |
| 12–<36 months             | 29.5                | 29.9        | 29.2      |          |
| ≥36 months                | 50.1                | 48.9        | 51.3      |          |
| Diabetes co-morbidity     |                     |             |           | <.0001   |
| Diabetic                  | 44.3                | 44.0        | 44.6      |          |
| Non-diabetic              | 55.7                | 56.0        | 55.4      |          |
| Facility profit status    |                     |             |           | <.0001   |
| For-profit                | 81.2                | 80.5        | 82.0      |          |
| Non-profit                | 18.8                | 19.5        | 18.0      |          |
| Facility chain status     |                     |             |           | <.0001   |
| Chain 1 (FP)              | 27.0                | 26.9        | 27.0      |          |
| Chain 2 (FP)              | 30.4                | 26.8        | 33.9      |          |
| Chain 3 (NP)              | 4.0                 | 4.1         | 3.9       |          |
| Medium chain              | 10.8                | 13.0        | 8.8       |          |
| Small/non chains          | 17.8                | 18.7        | 16.9      |          |
| Hospital-based (NP)       | 10.0                | 10.6        | 9.5       |          |
| Hematocrit value          |                     |             |           | <.0001   |
| <30%                      | 8.4                 | 7.4         | 9.4       |          |
| 30–<36%                   | 45.7                | 41.6        | 49.8      |          |
| ≥36%                      | 45.9                | 51.0        | 40.8      |          |

Notes: FP For-profit, NP Nonprofit.  
Base period from September 2004 to February 2007. Followup March 2007 to August 2009.  
FDA black box warning was issued in March 2007.  
*Patients months with missing hematocrit values are not included (when dose is withheld).  
P-value for Pearson’s chi-square test based on the difference between pre and post FDA warning period.

Trends in ESA treatment patterns across the study period were modeled using a general linear model with the monthly dose per week as the dependent variable and the month as the independent variable. Monthly prescription
rates for each patient were calculated by dividing the total ESA dose by the number of days in each dialysis claim (typically 30) and multiplying by 7 to calculate the weekly dose per month. These monthly ESA dose per week were then used to determine an average monthly ESA dose per week for the entire population.

An interrupted time series model using the AUTOREG procedure in SAS was used to evaluate changes in average ESA dosages in the 30 months prior (base) and 30 months subsequent (followup) to the FDA black box warning as follows [12]:

$$Y = \beta_0 + \beta_1 \cdot m1 + \beta_2 \cdot m2 + \beta_3 \cdot x1$$

Where $Y$ is the average ESA dose per week in each study month; $\beta_0$ estimates ESA prescribing at the beginning of the study period; $\beta_1$ estimates change in ESA prescribing in each month before the FDA warnings ($m1$ study month in period 1); $\beta_2$ estimates change in ESA prescribing in each month after the FDA warnings ($m2$ study month in period 2); $\beta_3$ estimates the change in ESA prescribing level following the FDA warnings ($x1$ is an indicator variable (0 for period one and 1 for period two)).

In our model, we took into account autocorrelations of the prescribing patterns along the time period. We built our model using a maximum likelihood method with two autocorrelation lags. The first order autocorrelation coefficient was significantly different from zero for almost all models. Time series sometimes exhibit seasonality or seasonal fluctuations. We tested for seasonality using proc spectra in SAS against white noise of the residuals from the models and found the residuals from our models were consistent with white noise that indicated that no extra seasonality modeling was needed [13]. In some cases, models need to be corrected for lagged effects (i.e., the effect of an intervention might take time to appear). However, in our study, the FDA black box warning was immediately reported to all nephrologists through the Dear Doctor letters, therefore no lag effects were entered into our main model, although possible random lag effects were modeled through serial correlations.

Results and discussion

Descriptive statistics

Across the study period, the study population was predominately elderly (49%), white (55%), male (54%), had a duration of dialysis greater than 3 years (50%), were nondiabetic (56%), received dialysis services from for-profit facilities (81%), from one of the two largest for-profit chains (27% and 30%, respectively), and had hematocrit values between 30-36%, within the FDA recommended range (comprising 46% of the study population) or higher (46%) (Table 1).

Although statistically significant, there were only minor differences in patient demographics (age, race and gender), duration of dialysis, and presence of diabetes between the base and followup study periods. While the proportion of patients who received dialysis services in for profit vs. not for profit centers remained nearly the same in the base
and followup periods, the largest dialysis chain, Chain 2, appeared to have grown substantially while medium sized chains (defined as chains with 10 to 100 facilities) decreased. There was also a shift in patient hematocrit values between the base and followup study periods; the proportion of patients with values greater than 36% was reduced from 51% to 41%, while those in the 30–<36% category increased from 42% to 50%. The proportion of anemic patients (<30%) remained ~7-9% during the study period. The aggregate number of patients receiving an ESA prescription (or a zero dose) per month was within the range of 215,444 to 238,697 throughout the study period (data not shown), suggesting no major exogenous change in terms of population size (Table 1).

**Unadjusted analyses and covariate effects**

Overall, there was a significant 7% decrease in average ESA dose between the base and followup 30-month periods for all dialysis patients (19,486 versus 18,191 units/week; Table 2). Most covariate strata also showed a decline in average dose between the two periods (P<0.0001), except for Chain 3. Notably, Chain 3 (the largest nonprofit chain), which administers ~4.4% of all ESA doses, administered the lowest mean ESA dose both in the base and follow up periods compared to other medium and large dialysis facilities. Overall, nonprofit and hospital-based facilities had the lowest average base and followup ESA doses. Hospital-based facilities are anomalous, however, due to their small size, sicker population, and disproportionate use of darbepoetin, a different form of ESAs that is longer acting was not included in this study.

Younger, nonwhite and new patients were most likely to be prescribed a higher ESA dose (≥30,000 units/week, reflecting the highest ESA dose quartile) (P<0.0001). Not unexpectedly, patients with the lowest hematocrit levels were significantly more likely to receive a higher ESA dose (P<0.0001). For profit facilities in general and the two largest for profit chains prescribed higher ESA doses (P<0.0001) (Table 2).

**Interrupted time series results**

A model was performed to determine if the average 7% observed decline in ESA dose was consistent with a change in dosing practice as of the FDA black box warning. Model results show the declining trend in month-to-month ESA dose was not statistically significant both before and after the FDA warnings. The drop in ESA dose level after the warnings was also not significant (Figure 1 and first row Table 3). Stratification by patient demographics, clinical and facility characteristics suggest a differential impact in the effect of the FDA black box warning on ESA prescribing. Only a few covariates had statistically significant findings linked to the FDA warnings. For example, patients with a hematocrit ≥36% had a declining month-to-month trend both before (−164 units/week, p<0.0001) and after the warnings (−80 U/wk, p=0.001), and a large drop in ESA levels after the warnings (−4,774 U/wk, p<0.0001) (Figures 2 and Table 3). In contrast, patients with a hematocrit <30% had a large increase in ESA dose level after the warnings (6,220 U/wk, p=0.013), consistent with an increasing month-to-month trend before the warnings (224 units/week, p=0.01). After the warnings, there was no significant decline in trend in ESA prescribing for patients with a hematocrit <30%. For patients within the FDA-recommended hematocrit range of 30–36%, the change in ESA level immediately after the warnings was not significant, but there was a decline in month-to-month trend after the warnings (−103 U/wk, p=0.014).

The other area of significant findings and wide variation in response to FDA warnings is dialysis facility organizational status (Figure 3 and Table 3). ESA prescribing trend in not-for profit facilities declined month-to-month before the warnings (−90 units/week, p=0.009), with a significant drop in ESA dose immediately after the warnings (−2,487 U/wk, p<0.015). In contrast, there was no evidence of change in ESA prescribing linked to the black box warning among for-profit facilities overall (Table 3). Each of the three largest US dialysis chains responded differently to the FDA warnings. Chain 1 patients experienced a declining month-to-month trend before (−90 units/week, p=0.004) and after the warnings (−103 U/wk, p=0.002), and a drop in ESA dose level after the warnings (−2,148 U/wk, p=0.017). Chain 2 patients experienced no change in ESA prescribing before or after the warnings. And Chain 3 patients experienced an increasing month-to-month trend before the warnings (94 U/wk, p=0.041), and an increase in the ESA dose level after the warnings (3,189 U/wk, p=0.016), followed by a flat insignificant trend.

Since ESA dose is sometimes withheld for a particular month as a means of lowering the hematocrit back to the target range, the extent to which dose withholding changed before and after the FDA black box warning is noteworthy. We found only a small increase in the frequency of patient months with zero ESA doses (withholding) in the 30 months after the FDA Black Box warning compared to the 30 months before (12.5% versus
Table 3 Results of interrupted time series model for selected variables

|                              | Change in ESA/week each month prior to black box warning | Change in ESA/week each month post black box warning | Change in ESA/week Level after black box warning |
|------------------------------|----------------------------------------------------------|------------------------------------------------------|--------------------------------------------------|
|                              | Beta1 | SD    | p-value | Beta2 | SD    | p-value | Beta3 | SD    | p-value |
| All                          | -37   | 25.8  | 0.162   | -41   | 27.6  | 0.146   | -882  | 773.9 | 0.260   |
| Hematocrit value             |       |       |         |       |       |         |       |       |         |
| < 30%                        | 224   | 84.1  | 0.010   | -137  | 85.7  | 0.114   | 6220  | 2423.0 | 0.013   |
| 30 - < 36%                   | 46    | 38.1  | 0.232   | -137  | 85.7  | 0.114   | 6220  | 2423.0 | 0.013   |
| ≥ 36%                        | -164  | 23.0  | <.0001  | -80   | 23.0  | 0.001   | -4744 | 648.2  | <.0001  |
| Facility profit status       |       |       |         |       |       |         |       |       |         |
| For-profit                   | -31   | 27.7  | 0.271   | -49   | 30.2  | 0.109   | 0.109 | 835.2 | 0.440   |
| Non-profit                   | -90   | 33.2  | 0.009   | -30   | 32.7  | 0.363   | -2487 | 985.4  | 0.015   |
| Facility chain status ^      |       |       |         |       |       |         |       |       |         |
| Large chains                 |       |       |         |       |       |         |       |       |         |
| Chain 1 (FP)                 | -90   | 30.0  | 0.004   | -103  | 31.8  | 0.002   | -2148 | 870.9 | 0.017   |
| Chain 2 (FP)                 | -15   | 35.4  | 0.673   | -27   | 37.7  | 0.480   | -61   | 1060.0 | 0.954   |
| Chain 3 (NP)                 | 94    | 44.9  | 0.041   | 43    | 44.6  | 0.343   | 3189  | 1288.0 | 0.016   |
| Medium chains                | 72    | 26.2  | 0.008   | -97   | 26.5  | 0.001   | 1703  | 7526.6 | 0.028   |
| Small/nonchain               | -6    | 24.8  | 0.797   | -49   | 24.9  | 0.055   | -432  | 723.3  | 0.553   |

Notes: SD Standard Deviation, FP For-profit, NP Nonprofit.

Variables included in Table 3 were selected based on one or more significant Beta value (p < 0.05).
Model intercept coefficient for all variables in Table 1 is significant (p < 0.0001). Since the time after the FDA warnings is not orthogonal to Beta3, the slope after the warnings (Beta2) is conditioned on the change in level (Beta3).

^ Large chains (Chain 1 - Chain 3) are defined as 100 or more units. Medium chains defined as 10 to ≤ 99 units. Small/Nonchains defined as < 10 units.

Figure 1 ESA units/week per month for the US hemodialysis population from September 2004 to August 2009.
11.5%; data not shown). In addition, we conducted sensitivity analyses including non-zero dose only in the analysis and the results were similar to those reported above. We also used ESA dose per administration (versus dose per week) as the study measure and found similar results. We conducted other models such as a segmented regression approach and the results were very similar to the ITS model reported in the paper.

**Conclusion**

Although there was a decline in ESA dose across the 60-month study period, the FDA black box warning issued in March 2007 did not appear to influence ESA prescribing for the overall dialysis population. However, for patients with the highest hematocrit values and for those receiving treatment in certain dialysis facilities, nephrologists and dialysis providers were more likely to heed the FDA black box warning.

The FDA black box warning issued for ESA therapy included the following important study results: “Patients with chronic kidney failure had an increased number of deaths and of non-fatal heart attacks, strokes, heart failure, and blood clots when ESAs were adjusted to maintain higher red blood cell levels (hemoglobin more than 12 g/dL).” A new patient medication guide accompanied the warnings and posed the following question and answer, ‘What is the most important information I should know about Epogen? Using Epogen can lead to death or other serious side effects’ [14]. Given these warnings, our findings raise questions as to why providers did not lower ESA doses further than we observed when faced with mounting evidence of risks [7,8,15-18]. Prior to the warnings, and during our study, although the FDA recommended a target hematocrit of 30 – 36%, studies suggested that providers often overshot the high end of this target range given Medicare’s reimbursement policy allowed hematocrit to be
as high as 39% [19,20]. ESA therapy was an important source of profit, particularly for large dialysis chains that were also able to recoup large rebates and receive discounts [21], producing the second largest source of facility income of ~22% [22]. For instance, a spike in ESA dose evident in the beginning of 2006, also confirmed by USRDS data [23], appears to be associated with a new lower payment method for ESA therapy that changed from a per-unit rate to a 6 percent above manufacturers’ average sales price (ASP) [24]. During our study period, ESA therapy continued to be reimbursed on a fee-for-service basis, creating a financial incentive for increased utilization of this therapy.

Although USRDS data show a decline in both ESA dose and hematocrit levels following the issuance of the FDA black box warning, it remained unclear, until now, whether these results were related to the FDA warnings or rather which groups, if any, benefited from the FDA warnings. Patients who had the highest hematocrit values showed the largest shift or decline in ESA dose level after the FDA warning with a drop of 4,744 U/week, perhaps because providers were concerned about their safety given publication of CHOIR [7] and CREATE [8] findings in mid-November 2006, showing potential harm and no benefit for ESA therapy, respectively. It is noteworthy, however, that on average the percentage of patients with a monthly hematocrit reading above 36% declined from 51% to 41%, following the FDA warnings. Given the appropriate goals of ESA therapy, two in five patients had hematocrit levels deemed unacceptably high in the 30 months following the FDA black box warning. For ESA-resistant patients, those with the highest doses
and hematocrit levels <30%, there was a large increase in ESA dose level immediately after the warnings (and no subsequent significant decline in ESA trend); findings contrary to the FDA black box warning. Perhaps providers felt justified not to decrease dose for their resistant patients after the warnings given the black box emphasis on avoiding transfusions which are sometimes triggered at a hematocrit threshold of ~27-30% for patients with serious co-morbidities [25]. High hematocrit levels appear to be of more concern to nephrologists than high ESA doses following the black box warnings. Implications of these findings require further investigation.

Variations in treatment practice patterns across more than 4,000 US dialysis facilities are well established and controversial [15,26-31]. In our study, nonprofit facilities overall had a declining trend before the warnings and a large drop in ESA dose immediately afterwards. In contrast, for-profit facilities overall that prescribed higher ESA doses in both the period before and after the FDA warnings compared to nonprofit facilities -- on average 19,514 versus 12,185 U/week in the post warning period -- did not change their ESA prescribing related to the FDA warnings. However, not all for-profit facilities responded similarly to the FDA warnings. During our study, two-thirds of dialysis patients received treatment in one of two large for-profit dialysis chains. Notably, one chain had significant declines in ESA doses consistent with FDA black box warnings and the other chain did not. Chains are owned by different entities that make individual corporate decisions regarding anemia protocols and anemia management goals among their patients.

Evidence of adverse events commonly emerges after a drug has been on the market for several years necessitating the issuance of a black box warning [32]. According to Green et al. [33], there are three categories of factors relevant to behavior change among physicians: predisposing factors (communicating or disseminating information); enabling factors (facilitating the desired change in the practice site); and reinforcing factors (by reminders or feedback). The model suggests that interventions that are most successful in changing physician practice are those that use enabling strategies or reinforcing methods in addition to predisposing or disseminating strategies. For example, a FDA black box warning on ESA use for oncology patients was also released on March 2007, and included a mandate that providers engage in a risk/benefit discussion with the patient and document that this discussion occurred by completing and signing the Patient Acknowledgment Form; a more stringent requirement that is absent from dialysis provider ESA prescribing. In contrast to the results presented herein, ESA use for oncology patients plummeted following the black box warning [34,35].

After nearly three decades of the same ESRD payment system, an enhanced ESRD Prospective Payment System (PPS) was initiated in January 2011 bundling separately billable items (primarily ESA therapy) into the larger dialysis composite rate [36]. Under PPS, facilities have no financial incentive to use more drugs than are clinically necessary. We anticipate that changes in reimbursement rates will have a greater impact on access and reduced exposure to ESA therapy compared to the March 2007 FDA black box warning. Indeed, early indications suggest that both ESA use [37] and hematocrit levels have been dramatically reduced since implementation of ESRD PPS [38].

Several study limitations are noteworthy, however. One, when ESRD patients are hospitalized, on average twice a year, information on ESA dosing is not available. Two, the analysis was confined to those individuals with Medicare as the primary payor, therefore the generalizability to other payers is limited. And three, because of the exploratory nature of our analysis, we did not adjust for the size of type I error rate in conducting multiple statistical tests. One way to address the potential threat regarding the validity of an interrupted time series by historical/secular shifts is to compare, in our case, ESA drug doses to drug dosing of other profitable injectable drugs that should not be affected by the FDA warning (e.g., injectable vitamin D or iron). After increasing each year since 1992 (including growth of 11–19% in 2002–2004) to reach nearly $2 billion, Medicare ESA costs (a surrogate for use) were stable in 2004–2007, and in 2008 declined to a pre-2004 level of $1.8 billion. Conversely, use of other intravenous drugs continued to increase in 2008 — 12% for IV vitamin D, 4.8% for IV iron, and 13.2% for other injectables [39].

ESA therapy had been both profitable for providers and controversial regarding benefits for nearly two decades. The extent to which a FDA black box warning highlighting important safety concerns influenced use of ESA therapy among nephrologists and dialysis providers was unknown. Our study found no evidence of changes in ESA prescribing for the overall dialysis population resulting from a FDA black box warning.

Competing interests
There are no financial or nonfinancial competing interests for any authors to report; specifically, no authors have any relationships with any companies that may have a financial interest in the information contained in the manuscript. Furthermore, all authors participated in the design, analysis, interpretation, writing, and/or editing of this study and have seen and approved the final version. Dr. Mae Thamer, as principal investigator and first author had full access to all of the data in the study and had final responsibility for the decision to submit for publication.

Authors’ contributions
MT and DC participated in the design of the study. OK created the analytic files, DL carried out the time series analysis, and MT drafted the manuscript. YZ carefully edited the paper and presentation of results. All authors read and approved the final manuscript.
Acknowledgements

The research for this article was supported in part, by the Agency for Healthcare Research and Quality (AHRQ) Grant SR03HS020572. Data was procured from funds available through AHRQ Grant R03HS018697. The data reported herein have been supplied by the US Renal Data System. The interpretation and reporting of these data are the responsibility of the authors and no way should be seen as the official policy or interpretation of the US government.

Source of funding

Agency for Healthcare Research and Quality (AHRQ) Grant SR03HS020572.

Author details

1. Medical Technology and Practice Patterns Institute, 5272 River Road, Suite 500, Bethesda, MD 20816, USA.
2. University of Texas School of Public Health, 1200 Herman PRESSLER Street, Suite 106D, Houston, TX 77030, USA.
3. Jangang University of Finance and Economics, Nanchang, China.

Received: 17 December 2012 Accepted: 7 August 2013

Published: 9 August 2013

References

1. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001, 12:2465–2473.

2. Lowrie EG, Huang WH, Leve NL, Liu Y: The relative contribution of measured variables to death risk among hemodialysis patients. In Death on hemodialysis. Edited by Friedman EA. New York: Dordrecht Kluwer Academic Publishers; 1994:121–141.

3. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999, 10:610–619.

4. U.S. Renal Data System: USRDS 2006 Annual Data Report; Atlas of end-stage Renal Disease in the United States. http://www.usrds.org/adr.htm.

5. US Government Accountability Office: End-Stage Renal Disease: CMS Should Monitor Access to and Quality of Dialysis Care Promptly after Implementation of New Bundled Payment System. Washington DC: GAO-10-295; 2010.

6. Besarab A, Bolton W, Browne JK, Egrie JC, Nissenson AR, Okamoto CM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:594–590.

7. Singh AK, Szczecz L, Tang KL, Bamhart H, Sapp S, Wolfson M, Reddan D, CHOR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085–2098.

8. Driehue TB, Locantelli F, Cynne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HJ, Scherhag A: CREATE investigators: normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355:2071–2084.

9. United States Renal Data System: USRDS 2009 Researcher’s Guide to the USRDS Database. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010.

10. Garey KW, Lai D, Dao-Tran TK, Gentry LO, Hwang LY, Davis BR: Vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery: an interrupted time series analysis. Antimicrob Agents Chemother 2008, 52:446–451.

11. Gillings D, Makuc D, Siegel E: Analysis of interrupted time series mortality trends: an example to evaluate regionalized perinatal care. Am J Pub Health 1981, 71:338–46.

12. SAS Institute Inc: SAS/STAT 9.2 User’s Guide. Cary, NC: SAS Institute Inc; 2008.

13. Lai D: White noise. International Encyclopedia of Social Sciences. 2nd edition 2008, 9:62–83.

14. MEDICATION GUIDE Epopogen® (Epo-poi-ten) (epoetin alfa) Amgen Manufacturing Limited, a subsidiary of Amgen Inc: One Amgen Center Drive Thousand Oaks, CA 91320–1799, Revised: 06/2011 ©1989–2011 Amgen Inc. http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088591.pdf

15. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D: Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005, 16:2180–2189.

16. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Carter P, Coyle D, Fine A, Handa P, Kingma L, Lau CY, Levin A, Mendelsohn D, Mushard N, Murphy B, Plante RK, Posen G, Wells GA: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000, 58:325–335.

17. Laquaglia A: A randomized double-blind study of recombinant human erythropoietin in anaemic hemodialysis patients. Canadian erythropoietin study group. Transplant Proc 1991, 23:1825–1832.

18. Furuland H, Linde T, Ahlmen J, Christensson A, Stornbom U, Danielson BG: A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003, 18:353–361.

19. Foley RN, Collins AJ: End-stage renal disease in the United States: an update from the United States renal data system. J Am Soc Nephrol 2007, 18:2644–2648.

20. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernán MA: Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 2007, 297:1667–1674.

21. Goozner M: The making and selling of a star drug. Chicago: Tribune News; 1999.

22. Office of Inspector General: Medicare Reimbursement for Existing End-stage Renal Disease Drugs. Washington DC: OIG: Publication ROB-03-04-00120; 2004.

23. US Renal Data System: USRDS 2007 Annual Data Report. Bethesda, MD: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007. Figure 5.9.

24. US Government Accountability Office: End Stage Renal Disease: Bundling Medicare’s Payment for Drugs with Payment for All ESRD Services Would Promote Efficiency and Clinical Flexibility. Washington DC: GAO-07-77; 2006. Nov 13.

25. Carles PA, Henry DA, Carson JL, Hebert PP, McColland B, Ker K: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion (Review). Cochrane Database Syst Rev 2010, 10, CD002042.

26. Fink JC, Blahut SA, Briglia AE, Gardner JF, Light PD: Effect of center- versus patient-specific factors on variations in dialysis adequacy. J Am Soc Nephrol 2001, 12:164–169.

27. Hirth RAM, Turenne N, Wheeler JR, Ma Y, Messana JM: Do resource utilization and clinical measures still vary across dialysis chains after controlling for the local practices of facilities and physicians? Med Care 2010, 48:726–732.

28. Tantrig N, Moorthy R, Tighiouart H, Meyer KB, Miskulin DC: Variation in fistula use across dialysis facilities: is it explained by case-mix? Clin J Am Soc Nephrol 2010, 5:307–313.

29. Garg PP, Frick KD, Diener-West M, Powe NR: Effect of the ownership of dialysis facilities on patients’ survival and referral for transplantation. N Engl J Med 1999, 341:1653–1660.

30. Zhang Y, Thamer M, Cotter D, Kharbbar S: Does higher injectable medication use mediate increased mortality? Health Serv Res 2013, 48:949–971.

31. Zhang Y, Thamer M, Cotter D: The effect of dialysis chains on mortality among patients receiving hemodialysis. Health Serv Res 2011, 46:764–776.

32. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH: Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002, 287:2215–2220.

33. Green L, Kreuter M, Deeds S, Partridge K: A diagnostic approach. Palo Alto, CA: Mayfield Press; 1980.

34. Amgen Media News Release. http://www.amgen.com/media/media_pr_detail.jsp?year=2007&releaseID=1067247

35. Bennett CL, McCoy JM, Henke M, Silver SM, MacDougall IC, Birgegard G, Luminari S, Creaavoid N, Schellekens H, Sartor O, Lai SJ, Armitage JG: Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park) 2010, 24:260–268.

36. US Government Accountability Office: End-Stage Renal Disease: Medicare Should Pay A Bundled Rate For All ESRD Items and Services. Washington DC: GAO-07-1050T; 2007.

37. EPOGEN® (Epoetin alfa) sales decreased 27 percent to $476 million in the third quarter of 2011 reflecting a decrease in dose utilization due to implementation of the bundled payment system. http://www.amgen.com/media/media_pr_detail.jsp?year=2011&releaseID=1620695

38. DOPPS Practice Monitor. http://www.dopps.org/DPM/Default.aspx

39. US Renal Data System: USRDS 2010 Annual Data Report, Atlas of End-Stage Renal Disease in the United States. http://www.usrds.org/adr.htm

Cite this article as: Thamer et al. Influence of safety warnings on ESA prescribing among dialysis patients using an interrupted time series. BMC Nephrology 2013 14:172.